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Abstract
Background: Due to long waiting periods for outpatient psychotherapy and the high resource requirements of
inpatient treatment, there is a need for alternative treatment programs for patients with depressive disorders. Thus,
we investigated the effectiveness of the “Bielefeld Outpatient Intensive Treatment Program of Depression” (BID) in
comparison with a typical inpatient treatment program by using a prospective quasi-experimental observational
study. We assumed (i) that both complex programs are effective in pre-post analyses after 6 weeks and (ii) that
inpatient treatment is more effective compared with the outpatient program.
Methods: Four hundred patients with depressive psychopathology – a majority with depressive episodes (ICD-10
F3X) - took part in the BID and 193 in the inpatient program. Different self- (i.e., BDI) and expert measures (i.e.,
MADRS) of psychopathology at baseline (t1) and 6 weeks later (t2) were applied to examine treatment effects.
Results: Treatment effects were high in separate analyses of both groups with Cohen’s d ranging from 1.10 to 1.76.,
while ANOVA comparative analyses did not reveal any significant differences between both treatment settings nor
did a set of independent covariates analyzed here. Response rates of BDI (p = .002) and MADRS (p = .001) were
higher in the outpatient group. Results indicate BID not to be inferior compared to an inpatient program, although
diverging pathways to treatment, higher rates of clinical recurrent depressive disorders and severe episodes as well
as lower rates of employment and partnership in the inpatient treatment group have to be considered.
Conclusion: Outpatient intensive treatment programs may represent a solution for patients needing more than a
treatment session once per week but less than a complex inpatient or day clinic program.
Keywords: Depression, Outpatient treatment, Inpatient treatment, Clinical trial, Effectiveness
Background
Depressive disorders represent a wide-spread mental dis-
order with a lifetime prevalence of 16–20% [1–4] and
are considered to be one of the most striking public bur-
dens of disease [5]. Chronic courses of depressive disor-
ders are frequent as well as long times of incapacity to
work [6, 7]. Thus, the access to effective guideline-
oriented treatments should not only be generally avail-
able but also early after onset of depression [8]. How-
ever, long waiting periods (at least 3 to 6months)
especially for psychotherapy are widespread [9]. In
addition, many health care systems focus on either low-
intensity and low-cost outpatient treatments with most
often not more than one short session per month or
maximum once per week psychotherapy sessions and on
the other hand on complex hospital (full or day clinic),
highly expensive treatments.
However, there are alternatives to purely outpatient
psychotherapeutic or inpatient forms of treatment for
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depressive disorders such as complex integrated out-
patient care models [10]. These treatment models con-
sist e.g. of cognitive-behavioral therapy sessions, if
indicated psychopharmacologic treatment and social in-
terventions by social workers, sport exercises, as well as
regular monitoring of the treatment progress. Aims of
such integrated care models are increasing quality and
cost-efficiency of treatment [11]. A moderate number of
such models were designed in the mental health field,
but only few were realized for more than two to 3 years
[12, 13], although Gunn and Diggens [14] in an overview
reported that multi-professional approaches with struc-
tured treatment plans and planned post-intervention
care do not only lead to increased inter-professional
communication but may also have a positive impact on
treatment outcomes in depression. Up to now and to the
best of our knowledge, there is almost no evidence on
the effectiveness of integrated care models in compari-
son to inpatient treatments (e.g. [15]), thus, more re-
search in this field is needed.
In the city of Bielefeld, Germany, a city with about
340.000 inhabitants, an integrated care model contract
was established in 2007 (valid up to now), in which the
outpatient service of our psychiatric clinic, regional
unions of physicians and psychotherapists working in
private practices (“Medi-OWL “and “APP”) and a work
group of health insurances, covering about 30% of indi-
viduals in the region (“ARGE BKK OWL”) participate.
The aforementioned new established integrated care
model is called „Bielefeld Intensive Outpatient Depres-
sion Program “(BID), which primarily focusses on the
treatment of patients with depressive disorders. BID of-
fers an outpatient, intensive, and multimodal treatment
over 6 weeks, which is described below. On the other
hand, the clinic offers a traditional 7 days per week in-
patient complex treatment program for patients with de-
pression without a fixed number of weeks but often also
lasting about 6 weeks (see below for more details).
Considering previous investigations having shown that
outpatient treatments were effective in (chronic) depres-
sive disorder [16–19] we assumed that both programs
are clinically effective in pre-post analyses after 6 weeks
of treatment. However, given that the inpatient treat-
ment offers substantially more specific and non-specific
therapies in 7 days per weeks as well as permanent avail-
ability of specialist personnel and immediate help in the
event of crises [20], we assumed that it is more effective
compared with the outpatient program.
Methods
Design and procedure
This is a prospective quasi-experimental observational,
i.e. non-randomized, controlled study [21], in which two
samples of patients with depressive disorders are
compared who are treated in an inpatient versus out-
patient complex intervention program. Thus, it repre-
sents a 2 × 2 factorial design with two times of
assessments (and 6 weeks of interventions in between)
as well as considering independent demographic and
clinical variables as covariates.
Noteworthy, patients pathways into these two pro-
grams were somewhat different due to the fact, that the
BID represents an integrated care program for patients
with a specific health insurance (BKK; see above as well
as Fig. 1): While in both programs patients could be
transferred by private practices (general practitioners,
psychiatrists, psychotherapists), consultation centers or
the hospital’s outpatient services directly, participants of
the inpatient program could be also transferred from a
hospital crisis intervention unit when primarily admitted
as a case of emergency.
Within the contract for participation in the BID pro-
gram patients gave their written consent into data ana-
lysis for an evaluation study while the inpatient
participants gave their written consent separately from
the admission contract. Standards of good clinical prac-
tice and the demands of the Declaration von Helsinki
were fulfilled.
Inpatient complex treatment program for depression
The multimodal treatment program consists of weekly
extensive visits (patient, psychiatrist, psychologist,
nurse), pharmacotherapy if indicated, cognitive behav-
ioral and in some cases additional psychodynamic psy-
chotherapy in single and group settings, training of
social competencies (once per week), sport exercises
(twice per week), relaxation training (twice per week),
imagination, occupational, art and/or music therapy
(each therapy offered twice per week), as well as 20–30
min sessions with the primary nurses (at least once per
week). Each patient receives his/her own schedule with
individual frequencies and combinations of treatment
services. However, each patient receives at least one (or
two) psychotherapeutic single and one group session per
week, one psychoeducation group session, one (to three)
at least 30 min lasting session with the individual pri-
mary nurse, as well as one or two other treatment ser-
vices (e.g. exercise therapy and imagination) per day.
Bielefeld outpatient intensive treatment program BID
The BID as an integrated care program focusses on
treatment of 18 to 65 years-old patients with a depres-
sive episode with (recurrent) depressive or bipolar disor-
ders (ICD-10 F31.x, F32.x, F33.x) as well as adjustment
disorders (F43.21) and Dysthymia (F34.1) [22], if clinical
severity of overall psychopathology is comparable. Major
aims of treatment are reducing depressive symptoms,
improving self-effectiveness, re-establishing the capacity
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to work (and return to job), and avoiding hospital ad-
missions for mental health reasons. Figure 1 describes
the pathway of the patients through the program.
In the inscription procedure, a screening is performed
by the institution with the primary contact with the pa-
tient, and – if positive – a primary examination follows
by a psychiatrist, who from now on overtakes the role of
a case manager (CM) with weekly contacts during the
intensive treatment episode. If the psychiatrist confirms
the diagnosis, a first contact with a psychologist of the
BID program takes place in the hospitals outpatient ser-
vice in order to check cognitive and language capacities,
expectations, aims, and motivation of the patient. Finally,
if the assumption of costs is declared by the health in-
surance (within 24 h), the six-weeks outpatient intensive
treatment episode starts.
It consists of cognitive-behavioral group (twice per
week) and single (once per week) therapy sessions, one
session per week with the CM psychiatrist (monitoring
the progress, psychopharmacologic treatment if needed),
contact with the social worker with a frequency
dependent of needs (e.g. rehabilitation issues, contacts to
the employee), sport exercises twice per week (Jogging/
Walking, gymnastics), and Qi Gong once per week. The
Fig. 1 Elements of the Bielefeld Outpatient Intensive Depression Program (BID) and inpatient depression program as well as pathways into,
within and out of the programs. Note: PT = Psychotherapy; T1/T2 = Times of measurement
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time schedule covers daily 1 to 3 sessions from Monday
to Friday.
The CBT group therapy according to Hautzinger und
Schaub [23, 24] consists of three parts, each lasting 2
weeks: 1. Psychoeducation and enhancing activities, 2.
cognitive therapy, and 3. Training of social competen-
cies. In the single therapy sessions, these contents are in-
dividualized and deepened. During the 6 weeks program
at least two case conferences take place for each patient.
Sport exercises and Qi Gong are continued after the
intensive treatment period for further 8 weeks, and up
to ten psychotherapy single sessions are optionally avail-
able, but this period is not issue of the present report.
Sample
In both settings, 18 to 65 years old patients were in-
cluded into the study, who fulfilled clinically assessed
diagnostic criteria as reported above. Further inclusion
criteria were sufficient German language capacities and
the explicit wish of the patients to take part in the treat-
ment. Exclusion criteria were comorbid psychotic disor-
ders, current substance use disorders, neurocognitive
disorders, and eating disorders.
The sample size needed for detecting a small to
medium effect in the two groups x two times design, i.e.
Cohen’s f = .15, α error p = .05, a power of 95% was cal-
culated as a total n = 148, i.e. n = 74 per treatment group
(Program G*Power [25];. Figure 2 reports the develop-
ment of the actual sample sizes in both treatment
groups.
The samples at t1 consisted of 400 participants in the
BID and 207 participants in the inpatient groups, from
whom only 19 (4.8%) and 21 (10.1%), respectively, did
not completed treatment.
Assessments
At t1 diagnoses according to ICD-10 were clinically
assessed by fully educated psychiatrists or clinical psy-
chologists in both groups and, in addition, by using the
German version of the International Checklists for ICD-
10 [26]. Apart from assessment of demographic data at
t1, the following instruments were used at t1 and t2 in
both groups:
Depression: Beck Depression Inventory (BDI-II) [27,
28] and Montgomery Asberg Depression Rating Scale
(MADRS) [29, 30].
Fig. 2 Flow-Chart reporting sampling in the two treatment groups
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Overall burden of psychopathology: Symptom Check-
list SCL-90-R, German version [31], the Global Severity
Index (GSI) is reported here.
General functioning: Global Assessment of Function-
ing Scale GAF (DSM-IV [32],).
Analyses
For comparing completers and non-completers within
both groups as well as for comparisons between groups
χ2-tests and T-tests were performed. Treatment effect-
iveness within the two treatment groups were analyzed
by using Cohen’s d basing on within-group pre-post T-
tests. Effect sizes are interpreted according to the classi-
fication of Cohen [33] with d = 0.2 indicating a small,
d = 0,5 indicating a moderate, and d > 0.8 indicating a
large effect. In order to compare effectiveness between
both treatment groups 2 (groups) × 2 (times) repeated
measures ANOVAs were performed with group as
between-subjects factor and time as within-subjects
factor. Independent variables, which showed significant
differences between groups at t1 were included as covar-
iates. Analyses included interaction effects time x groups
as well as time x group x covariates.
For the intention-to-treat analysis, we imputed missing
data for outcome variables by using the expectation
maximization procedure. The proportion of missing data
on outcome variables ranged from 4.2% (BDI baseline)
to 19.6% (GAF at t2). Littles’s missing completely at
random-test revealed that missing outcome data were
completely at random, χ2(211) = 228.60, p = .19. All ana-
lyses were repeated using listwise deletion method, yield-
ing comparable results (data available on request). All
analyses were performed by using the Statistical Soft-
ware for the Social Sciences (SPSS Version 25).
Results
Sample characteristics
Completers and non-completers within the inpatient
(n = 21 non-completers) and the BID group (n = 19 non-
completers) did not differ significantly regarding age,
gender, partnership, school education, current employ-
ment status, psychotropic medication, rate of recurrent
depressive disorders and baseline scores in most out-
come measures, i.e. all p > .09 (data available on request).
In the BID group, non-completers were somewhat more
often lower educated (χ2 = 4.52; df = 1; p = .03). In the in-
patient group, non-completers had somewhat more
often a mild to moderate depression (χ2 = 5.92; df = 1;
p = .02) and showed a lower MADRS score at baseline
(t(191) = 3.00, p = .003).
Table 1 reports demographic and clinical characteris-
tics of the two treatment groups at t1. There were not
any significant differences regarding age, gender, educa-
tion, number of clinical psychiatric diagnoses and
current suicidal thoughts. However, patients in the in-
patient treatment group lived less frequently with a part-
ner (χ2(1) = 18.55, p < .001), were less frequently
employed (χ2(1) = 26.98, p < .001) suffered more often
from recurrent depressive disorders (χ2(1) = 44.77,
p < .001) and more often from current severe depressive
episodes than patients in the BID group (χ2(1) = 170.86,
p < .001). In addition, inpatients had a lower global func-
tioning (GAF: t(591) = 11.51, p < .001) and took more
often prescribed psychotropic medication, most often
antidepressants (χ2(1) = 23.05, p < .001) than BID partici-
pants. However, groups did not differ in terms of self-
reported or therapist-evaluated severity of depression
(BDI: t(328.60) = − 0.54, p = .59; MADRS: t(591) = −.61,
p = .57, for M and SD see Table 2).
In order to analyze potential heterogeneity within the
inpatient group, we subdivided this sample in those pa-
tients who were admitted directly from home and those
who were transferred from the crisis intervention unit:
At t1 neither self-reported depression differed (BDI: dir-
ect admission M = 30.2, SD = 10.9; transfer M = 30.4,
SD = 12.7; t(191) = − 0.08, p = .93) nor did therapist-rated
depression (MADRS: direct admission subgroup M =
26.7 SD = 5.7; transferred subgroup M = 28.2 SD = 8.4;
t(44.08) = − 1.06, p = .30). In addition, in the transferred
subgroup the number of hospital days before transfer to
the inpatient program was not significantly associated
with the severity of depression at t1 (BDI: r = −.21,
p = .23; MADRS: r = −.22, p = .19).
Effectiveness of treatment
After 6 weeks of treatment pre-post analyses yielded in
significant clinical improvements within both groups
with strong effect sizes regarding all characteristics mea-
sured (i.e. Cohen’s d > 1) (Table 2).
Mixed repeated measures ANOVAs did not reveal any
significant time x group interaction effects for the clin-
ical measurements (see Table 3). In addition, the covari-
ates severity of diagnoses, recurrent disorder versus
single episode, medication (yes/no), family, and employ-
ment status did not have any significant influence on
these results. In other words, we did not find any differ-
ences of effectiveness between the two treatment groups.
Response rates (proportion of participants with a T2
score < 50% of that at T1) were also analysed focusing
on the core depression characteristics. BDI self-rating
data yielded in 41.8% responders in the outpatient and
28.8% in the inpatient group, indicating a larger rate of
responders in the outpatient group (χ2 = 9.25, df = 1,
p = .002). Interviewer-based MADRS scores also yielded
a larger rate of responders in the outpatient group
(46.6%) than in the inpatient one (30.9%) (χ2 = 13.06,
df = 1, p < .001).
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Costs
While the inpatient treatment’s costs for 6 weeks were about
42 days x roughly 250 €= about 10.500 €, the BID program’s
costs for the 6 weeks intensive treatment period (plus
weekly excercises for further 8 weeks) were about 3000 € ac-
cording to the contract with the health insurances.
Discussion
The large treatment need of patients with depression is
not sufficiently met in many countries. Especially, inten-
sive and complex outpatient offers are missing for pa-
tients with moderate to severe disorders, for whom long
periods of waiting and/or low intensity treatment
Table 2 Pre-post measures and within-group effect sizes in the two treatment settings; n = 400 (BID) n = 193 (inpatients)
Group Time 1
M (SD)
Time 2
M (SD)
T-tests Cohen’s d1
Severity of self-rated Depression (BDI) BID 29.8 (9.5) 17.4 (10.5) t (399) = 25.7; p < .001 −1.36
Inpatient 30.3 (11.2) 20.2 (12.0) t (192) = 18.4; p < .001 −1.36
Severity of depression assessed by the therapist (MADRS) BID 26.6 (6.4) 13.9 (7.5) t (399) = 32.5; p < .001 −1.76
Inpatient 27.0 (6.3) 15.5 (4.7) t (192) = 23.2; p < .001 − 1.49
Global Functioning (GAF) BID 52.5 (8.6) 64.8 (11.5) t (399) = −21.1; p < .001 1.25
Inpatient 43.9 (8.3) 58.8 (7.7) t (192) = −20.9; p < .001 1.45
Global burden of psychopathology (SCL-90-R GSI) BID 73.3 (8.0) 62.7 (12.0) t (399) = 20.2; p < .001 −1.33
Inpatient 73.4 (8.4) 66.2 (11.1) t (192) = 12.5; p < .001 − 1.10
Legend: 1d ≥ 0.2 small effect, d ≥ 0.5 moderate effect, d ≥ 0.8 large effect (marked)
Table 1 Sample characteristics at t1
BID (N = 400) Inpatient (N = 193)
Missings (n) M (SD) or n (%) M (SD) or n (%) Statistics (df)
Female (%) 0 245 (61.3) 116 (60.1) χ2 (1) = 0.07; p = .79
Referral, n (%) 19 (3.2)
General Practitioner (private practice) 9 (2.3) 8 (4.2)
Psychiatrist (private practice) 269 (70.2) 106 (55.5)
Psychotherapist (private practice) 19 (5.0) 9 (4.7) χ2 (6) = 94.11; p < .001
Outpatient Service (hospital) 65 (17.0) 22 (11.5)
Hospital transfer 0 39 (20.4%)
Counselling of Health Insurance 13 (3.4) 0
Others 8 (2.1) 7 (3.7)
Age; M (SD) 0 43.1 (11.2) 41.5 (12.2) t (351.82) = 1.56; p = .11
Partnership; n (%) 21 (3.5) 240 (63.2) 85 (44.3) χ2 (1) = 18.55; p < .001
Highest school educationa; n (%) 14 (2.4) 173 (44.7) 86 (44.8) χ2 (1) = 0.000; p = .98
Current employment; n (%) 21 (3.5) 277 (72.9) 98 (51.0) χ2 (1) = 26.98; p < .001
Clinical diagnoses; n (%) 12 (2.0)
Low depressive episode/Dysthymia/Adjustment disorder 62 (15.7) 3 (1.6%)
Moderate depressive episode 291 (73.5) 61 (33.0) χ2 (2) = 194.44; p < .001
Severe depressive episode 43 (10.9) 121 (65.4)
Number of diagnoses; M (SD) 1.2 (0.4) 1.3 (0.5) t (323.84) = − 0.97; p = .30
Severity of depression (low to moderate versus severe); n (%) 2 (0.3) 346 (86.5) 64 (33.5) χ2 (1) = 170.86; p < .001
Recurrent depressive disorder; n (%) 1 (0.2) 67 (16.8) 81 (42.2) χ2 (1) = 44.77; p < .001
Suicidal thoughtsb; n (%) 45 (7.6)
- Score 1 159 (43.6%) 90 (49.2%) χ2 (3) = 6.41;
- Scores 2 and 3 19 (5.2) 17 (9.3)
Psychotropic Medicationc; n (%) 45 (7.6) 291 (80.6) 179 (95.7) χ2 (1) = 23.05; p < .001
Legend: ain Germany Abitur; bSuicidal thoughts = Item 9 of the Beck Depression Inventory BDI-II (1 = “I have thoughts of killing myself, but I would not carry them
out”, 2 = “I would like to kill myself”, 3 = “I would kill myself if I had the chance”); cprescribed medication
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modalities are not acceptable and/or not sufficient. Con-
sequently, these patients are often admitted to mental
hospitals and/or day clinics, although such high intensive
treatments are not required in all cases. In addition,
studies are missing, which evaluate and compare com-
plex outpatient and inpatient programs for patients with
depression. Here we present a complex inpatient pro-
gram and the outpatient intensive program BID, both of
them following the current national as well as inter-
national guidelines for the treatment of depression.
In a quasi-experimental design, we compared out-
comes after 6 weeks and as assumed found that both
programs are comparably high effective in within-groups
pre-post analyses regarding the degree of the depressive
syndromes, overall burden of psychopathology as well as
global functioning. We had not expected the observed
consistently high effect sizes with d > 1 [34], which may
be due to the intensity of the programs. However, our
data do not support our assumption that the inpatient
program is more effective than the outpatient program
BID, although the first one being more complex, inten-
sive, and more expensive.
Noteworthy, inpatients differed from the BID patients at
t1 in terms of current partnership, current employment,
diagnoses of recurrent depressive disorders as well as
current severe episodes (but not acute suicidality), and of
the rate of subjects with psychotropic medication. It may
be that recurrent episodes lead to social withdrawal or
even generally to a lower global functioning [35]. On the
other hand, the BID program may be more attractive for
patients who are currently employed. However, all these
characteristics were not found to significantly influence
the results of repeated-measures covariance analyses.
Noteworthy, we observed rather a low dropout rate during
the 6 weeks of intensive treatment, which demonstrates its
suitability for patients with depressive disorders.
As national and most international guidelines indicate,
the efficacy and effectiveness of cognitive-behavioral
therapy in depressive disorders as well as of combina-
tions with antidepressive medication in severe depres-
sion were reported in a substantial amount of studies
and meta-analyses [17–19, 36–38]. Group therapies were
offered in both settings of the present study and were
also shown to be effective [39] as well as did sport exer-
cises and relaxation trainings [40, 41].
There are some examples for the effectiveness of
integrated care programs in (mental) health problems
[42–45]. However, to the best of our knowledge, there
Table 3 Results of repeated measures ANOVAs and analyses of covariance comparing the treatment groups with independent
covariates analyzed separately; sample sizes for main ANOVAs without covariates were n = 400 (BID), n = 193 (inpatients); df = 1 in
dependent variables; df = 2 in covariates; error df = 515
Outcome Effects of time Effects of group Interaction time x group Interactions time x group x covariate
Severity of self-rated depression
(BDI score)
F = 23.01
p < .001
F = 0.21
p = .65
F = 1.33
p = .25
Severitya F = 1.91; p = .15
Recurrentb F = 1.51; p = .22
Family Statusc F = 1.16; p = .32
Employmentd F = 1.93; p = .15
Medicatione F = 1.56; p = .21
Severity of depression assessed by the
therapist (MADRS)
F = 26.52
p < .001
F = 1.19
p = .28
F = 0.51
p = .35
Severitya F = 0.51; p = .60
Recurrentb F = 0.72; p = .49
Family Statusc F = 0.29; p = .75
Employmentd F = 0.63; p = .53
Medicatione F = 2.00; p = .14
Global Functioning (GAF) F = 22.84
p < .001
F = 2.19
p = .14
F = 1.08
p = .30
Severitya F = 1.29; p = .28
Recurrentb F = 1.01; p = .36
Family Statusc F = 0.44; p = .65
Employmentd F = 1.81; p = .17
Medicatione F = 1.27; p = .28
Global burden of psychopathology
(SCL-90-R GSI)
F = 26.72
p < .001
F = 0.00
p = .998
F = 0.10
p = .75
Severitya F = 1.56; p = .21
Recurrentb F = 1.22; p = .30
Family Statusc F = 1.06; p = .35
Employmentd F = 2.46; p = .09
Medicatione F = 0.64; p = .53
Legend:aRegarding diagnosis (low to moderate versus severe depressive episode); bSecond or more versus first episode; cpartnership yes/no; dcurrent employment
yes/no; ePsychotropic medication yes/no
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are not any investigations on outcome differences be-
tween outpatient and inpatient complex treatment pro-
grams [8]. Because of the inpatient treatment of
depression covering 24 h of care and its greater com-
plexity with more individualized services for the patients,
we assumed its higher effectiveness compared to the less
complex outpatient program. Our results do not support
this assumption, but this conclusion may only be valid
with some limitations: In the inpatient group, clinical
diagnoses complemented by the International Diagnostic
Checklists indicated a higher rate of current severe epi-
sodes as well as of recurrent depressive disorders than in
the BID group. However, BDI and MADRS did not re-
veal substantial between-groups differences at t1. An ad-
vantage of BID is its higher flexibility with rather short
waiting periods prior to treatment of no more than two
to 3 weeks, so that the symptoms may be less often
chronic and the prognosis more favorable [46, 47]. In
the inpatient group, waiting periods varied substantially
up to 8 weeks periods between the first contact and ad-
mission in most patients, while others were admitted to
the crisis intervention unit and transferred to the treat-
ment unit directly. This latter group of patients appar-
ently needed at least an initial inpatient treatment
because of a threatening crisis.
Regarding the differences of costs for the two treat-
ment programs, cost-effectiveness relation of the out-
patient BID program was substantially more favorable
than that of the inpatient program.
Limitations
There are some limitations with this study. First, only
members of one group of general health insurances (the
so called ARGE BKK OWL) had access to the BID pro-
gram, so we cannot completely exclude an inherent sys-
tematic bias. Second, randomization to the treatment
conditions was not possible. A randomized controlled
trial is needed to exclude bias and support our results
more definitely. Third, our data do not give information
about ongoing effects beyond the end of the 6 weeks of
treatment. Fourth, we are not able to analyze, which ele-
ments of the treatment programs are more or less im-
portant regarding the overall treatment effects. We can
only state that the inpatient program included more
therapeutic offers per week than the BID program. Fifth,
we had no wait-list control group and consequently are
not able to evaluate the relative superiority of treatments
used here compared with placebo effects. However, the
effect sizes determined in our study substantially
exceeded effect sizes of wait-list control groups that
were published in a meta-analytical review [48]. Finally,
our results do not refer to patients with currently severe
comorbid disorders because they were excluded from
analyses.
Conclusions
Even if considering a variety of limitations with this
study as well as considering that a substantial proportion
of patients with depressive disorders do primarily need a
hospital admission, our results underline that an inten-
sive and complex outpatient treatment over 6 weeks is
not generally less effective than an inpatient program in
a large proportion of patients concerned. In addition,
costs for BID are substantially lower.
Abbreviations
ANOVA: Analysis of Variance; APP: Arbeitskreis niedergelassener
Psychologischer Psychotherapeuten in Bielefeld (Workgroup of psychological
psychotherapists in private practices in Bielefeld); ARGE BKK
OWL: Arbeitsgemeinschaft der Betriebskrankenkassen Ostwestfalen-Lippe
(Work Group of health insurances Eastern Westfalia-Lippe); BDI: Beck
Depression Inventory; BID: Bielefeld Outpatient Intensive Treatment Program
of Depression; CBT: Cognitive Behavioral Therapy; CM: Case Manager;
GAF: Global Assessment of Functioning; MADRS: Montgomery Åsberg
Depression Rating Scale; Medi-OWL: Verband der niedergelassenen Ärzte
und Psychotherapeuten in Ostwestfalen-Lippe (Union of physicians and psy-
chotherapists in private practices in Eastern Westfalia-Lippe); SCL-90-R
GSI: Symptom Checklist 90 items revised version; Global Severity Index
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